Superinfections in patients treated with Teicoplanin as anti‐SARS‐CoV‐2 agent

Ceccarelli, Giancarlo; Alessandri, Francesco; Oliva, Alessandra; Dell’Isola, Serena; Rocco, Monica; Ruberto, Franco; Pugliese, Francesco; d’Ettorre, Gabriella; Venditti, Mario

doi:10.1111/eci.13418

Cited by 12 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydroxychloroquine (HCQ) and antivirals were used in 33/45 (73.3%) and 7/45 (15.5%) subjects, whereas azithromycin and teicoplanin ( 15 – 17 ) were used in 19/45 (42.2%) and 9/45 (20%) subjects, respectively. As adjunctive therapy, tocilizumab, steroids and enoxaparine were administered in 21/45 (46.6%), 15/45 (33.3%) and 24/45 (53.3%) subjects, respectively.…”

Section: Resultsmentioning

confidence: 99%

Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19

et al. 2021

Self Cite

View full text Add to dashboard Cite

Microbial translocation (MT) and intestinal damage (ID) are poorly explored in COVID-19. Aims were to assess whether alteration of gut permeability and cell integrity characterize COVID-19 patients, whether it is more pronounced in severe infections and whether it influences the development of subsequent bloodstream infection (BSI). Furthermore, we looked at the potential predictive role of TM and ID markers on Intensive Care Unit (ICU) admission and in-hospital mortality. Over March–July 2020, 45 COVID-19 patients were enrolled. Markers of MT [LPB (Lipopolysacharide Binding Protein) and EndoCab IgM] and ID [I-FABP (Intestinal Fatty Acid Binding Protein)] were evaluated at COVID-19 diagnosis and after 7 days. As a control group, age- and gender-matched healthy donors (HDs) enrolled during the same study period were included. Median age was 66 (56-71) years. Twenty-one (46.6%) were admitted to ICU and mortality was 22% (10/45). Compared to HD, a high degree of MT and ID was observed. ICU patients had higher levels of MT, but not of ID, than non-ICU ones. Likewise, patients with BSI had lower EndoCab IgM than non-BSI. Interestingly, patients with high degree of MT and low ID were likely to be admitted to ICU (AUC 0.822). Patients with COVID-19 exhibited high level of MT, especially subjects admitted to ICU. COVID-19 is associated with gut permeability.

show abstract

Section: Resultsmentioning

confidence: 99%

Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the clinics, teicoplanin has been applied to treat Staphylococcus aureus superinfections that may occur as major complication in COVID-19 patients [ 121 ] that simultaneously might act antiviral. However, an effect on SARS-CoV-2 remains to be shown [ 122 ].…”

Section: Targeting Proteolytic S Protein Activationmentioning

confidence: 99%

Peptide and peptide-based inhibitors of SARS-CoV-2 entry

Schütz

Ruiz‐Blanco

Münch

et al. 2020

Advanced Drug Delivery Reviews

159

138

View full text Add to dashboard Cite

To date, no effective vaccines or therapies are available against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of coronavirus disease 2019 (COVID-19). Due to their safety, efficacy and specificity, peptide inhibitors hold great promise for the treatment of newly emerging viral pathogens. Based on the known structures of viral proteins and their cellular targets, antiviral peptides can be rationally designed and optimized. The resulting peptides may be highly specific for their respective targets and particular viral pathogens or exert broad antiviral activity. Here, we summarize the current status of peptides inhibiting SARS-CoV-2 entry and outline the strategies used to design peptides targeting the ACE2 receptor or the viral Spike protein and its activating proteases furin, transmembrane serine protease 2 (TMPRSS2), or cathepsin L. In addition, we present approaches used against related viruses such as SARS-CoV-1 that might be implemented for inhibition of SARS-CoV-2 infection.

show abstract

“…[6][7][8] Based on the aforementioned, teicoplanin was suggested as an alternative complementary option to treat also SARS-CoV-2 infected patients. [9][10][11] Moreover, teicoplanin is a possible choice for treatment of Staphylococcus aureus superinfection, a major complication of respiratory viral infections. 12 Here we present the first retrospective analysis of a real-life cohort of critically ill patients with COVID-19 complementary treated with teicoplanin, used with a double purpose: as empiric treatment of possible S. aureus superinfection and as antiviral agent for SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

The role of teicoplanin in the treatment of SARS‐CoV‐2 infection: A retrospective study in critically ill COVID‐19 patients (Tei‐COVID study)

Ceccarelli

Alessandri

Oliva

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID-19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID-19 in critically ill patients. Fifty-five patients with severe COVID-19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei-COVID group), while 21 without teicoplanin (control group). Crude in-hospital Day-30 mortality was lower in Tei-COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p = .654). No statistically significant differences in length of stay in the ICU were observed between Tei-COVID group and control group (p = .248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei-COVID group and 57.1% of control group, without statistical difference. Serum C-reactive protein level was significantly reduced in Tei-COVID group compared to control group, but not other biochemical parameters. Finally, Gram-positive were the causative pathogens for 25% of BSIs in Tei-COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed.Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS-CoV-2, previously documented, is probably more effective at early clinical stages.

show abstract

Superinfections in patients treated with Teicoplanin as anti‐SARS‐CoV‐2 agent

Cited by 12 publications

References 9 publications

Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19

Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19

Peptide and peptide-based inhibitors of SARS-CoV-2 entry

The role of teicoplanin in the treatment of SARS‐CoV‐2 infection: A retrospective study in critically ill COVID‐19 patients (Tei‐COVID study)

Contact Info

Product

Resources

About